anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To obtain a flutamide composition excellent in eluting ability and absorbability in vivo and capable of reducing adverse effects and a dose required for clinical effects in a therapy of prostatic cancer. SOLUTION: This flutamide composition contains flutamide and a nonionic surfactant as essential ingredients, or a lower polyhydric alcohol ester of a fatty acid can be further added as the essential ingredient. The nonionic surfactant preferably dissolves 100-150mg flutamide at 20 deg.C and polyoxyethylene-cured castor oil is cited as an example. The lower polyhydric alcohol ester of a fatty acid dissolves at least >=20mg flutamide/g ester and a middle chain fatty acid triglyceride is cited as an example. To 1 pt.wt. flutamide, 0.5-10 pts.wt. nonionic surfactant and 0.3-15 pts.wt. lower polyhydric alcohol ester of a fatty acid can be added. The dose is, e.g. 40-80mg flutamide capsule which can be administered once or twice a day.
ICU patients (post-operative and none operative patients) will be enrolled in the study. They are followed up until the end of ICU stay or, for a maximum of 60 days.
FIELD: confectionery industry. SUBSTANCE: candy mass comprises core of soft caramel, stabilizing layer of soft caramel adapted for covering said core, and panned coat. Candy mass also comprises sweetener, such as hydrated isomaltose or mixture of 1,1-GPS, 1,1-GPM and 1,6-GPS. Method involves producing light caramel mass for core and stabilizing layer mass; drawing or blowing soft caramel mass for core and stabilizing layer mass; joining said masses; forming, with following panning of produced cores. Method provides stable form of core to allow cores to be molded and panned. Obtained candies are not too soft and do not stick to teeth, at the same time candies are not too hard so that they may be chewed. Panned coat is difficult to be sheared and is crunchy. Individual candies do not adhere to one another. EFFECT: increased efficiency and improved quality of product. 14 cl, 2 ex
Participants in Sub-study 3 who meet eligible criteria for Sub-study 4 will receive risankizumab dose 1 or dose 2 via on-body injectors on Weeks 0,8 and 16. Beginning Week 24, participants will receive risankizumab dose 1 or dose 2 via pre-filled syringes Q8W.
This invention provides a riveted device. The riveted device includes a first riveted member and a second riveted member. The first riveted member has a connecting surface and a circular portion formed by drawing a punching hole. The circular portion protrudes from the connecting surface and includes a first riveted portion with a first outer diameter and a second riveted portion with a second outer diameter. The first outer diameter is greater than the second outer diameter. One end of the first riveted portion is connected to the connecting surface, and the other end is connected to the second riveted portion. The second riveted member has a through hole. The circular portion passes through the through hole, and the second riveted portion is turned outward. Thus the second riveted member is disposed between the second riveted portion and the connecting surface.
Drug: Control Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
The bean yellow mosaic virus (BYMV) is one of the most serious economic diseases affecting faba bean crop production. Rhizobium spp., well known for its high nitrogen fixation capacity in legumes, has received little study as a possible biocontrol agent and antiviral. Under greenhouse conditions, foliar application of molecularly characterized Rhizobium leguminosarum bv. viciae strain 33504-Borg201 to the faba bean leaves 24 h before they were infected with BYMV made them much more resistant to the disease while also lowering its severity and accumulation. Furthermore, the treatment promoted plant growth and health, as evidenced by the increased total chlorophyll (32.75 mg/g f.wt.) and protein content (14.39 mg/g f.wt.), as well as the improved fresh and dry weights of the plants. The protective effects of 33504-Borg201 greatly lowered the levels of hydrogen peroxide (H2O2) (4.92 µmol/g f.wt.) and malondialdehyde (MDA) (173.72 µmol/g f.wt.). The antioxidant enzymes peroxidase (1.58 µM/g f.wt.) and polyphenol oxidase (0.57 µM/g f.wt.) inhibited the development of BYMV in plants treated with 33504-Borg201. Gene expression analysis showed that faba bean plants treated with 33504-Borg201 had higher amounts of pathogenesis-related protein-1 (PR-1) (3.28-fold) and hydroxycinnamoyl-CoA quinate hydroxycinnamoyltransferase (4.13-fold) than control plants. These findings demonstrate the potential of 33,504-Borg201 as a cost-effective and eco-friendly method to protect faba bean plants against BYMV. Implementing this approach could help develop a simple and sustainable strategy for protecting faba bean crops from the devastating effects of BYMV.
During chronic wound healing, the inflammatory phase can endure for extended periods, heavily impeding or halting the process. Regular inspections and dressing changes are crucial. Modern dressings like hydrogels, hydrocolloids, and foam provide protection and an optimal healing environment. However, they have limitations in offering real-time wound bed status and healing rate. Evaluation relies heavily on direct observation, and passive dressings fail to identify subtle healing differences, preventing adaptive adjustments in biological factors and drug concentrations. In recent years, the clinical field recognizes the value of integrating intelligent diagnostic tools into wound dressings. By monitoring biomarkers linked to chronic wounds' inflammatory state, real-time data can be captured, reducing medical interventions and enabling more effective treatment plans. This fosters innovation in chronic wound care. Researchers have developed smart dressings with sensing, active drug delivery, and self-adjustment capabilities. These dressings detect inflammatory markers like temperature, pH, and oxygen content, enhancing drug bioavailability on the wound surface. As wound healing technology evolves, these smart dressings hold immense potential in chronic wound care and treatment. This comprehensive review updates our understanding on the role and mechanism of action of the smart dressings in chronic refractory wounds by summarizing and discussing the latest research progresses, including the intelligent monitoring of wound oxygen content, temperature, humidity, pH, infection, and enzyme kinetics; intelligent drug delivery triggered by temperature, pH, near-infrared, and electricity; as well as the intelligent self-adjustment of pressure and shape. The review also delves into the constraints and future perspectives of smart dressings in clinical settings, thereby advancing the development of smart wound dressings for chronic wound healing and their practical application in clinical practice.
The invention provides a bioluminescent nanoprobe for long-term imaging of Fibroblast Activation Protein (FAP) in an organism. The bioluminescent nano probe comprises an amphiphilic block polymer and fluorescein loaded with the amphiphilic block polymer and having a bioluminescent function. The block polymer comprises: a hydrophilic polymer end, a lipophilic lactide end and an active peptide chain as a connecting region. The FAP-responsive bioluminescent nano probe provided by the invention has the advantages of long imaging time, high sensitivity, good selectivity and biocompatibility and the like. The invention also provides a preparation method and application of the probe. In vitro experiment results prove that the bioluminescence intensity and the FAP concentration present a good linear relationship, and the probe can be used for quantitatively detecting FAP. Meanwhile, compared with the traditional organic small-molecule bioluminescent probe, the nano probe is not easy to degrade and discharge by organisms, and long-time bioluminescent imaging of cell endogenous FAP is realized. In conclusion, the bioluminescent nano probe prepared by the invention is an effective tool for quantitatively detecting and imaging FAP in tumor cells for a long time.
Participants assigned to the yogurt group were provided with a biweekly supply of yogurt at every other visit and were directed to consume one serving daily (5-ounce, 141 grams) and to store the remaining yogurt at 40˚ F or lower until consumed. Additionally, all participants were instructed to keep a log of any yogurt consumption time and changes to bowel health. The ingredients of the yogurt include Pasteurized Grade A Milk, Cane Sugar, Yogurt Cultures (L. bulgaricus, S. thermophilus), and Vanilla Extract. The intervention meets the Codex Alimentarius definition of yogurt. In addition, the yogurt lacked preservatives, added fruit or pectin, was not enriched with added prebiotics or probiotics.
Bipolar disorder is a chronic mental illness that affects 1-2% of the general population. Lithium and valproate are effective for treatment of acute mania for many patients. However up to half of patients do not respond adequately to currently approved treatments in the acute phase of mania. More effective treatment for mania are need. Imbalance in cholinergic and adrenergic tone has long been postulated in the pathophysiology of bipolar disorder. In the pathophysiology of mania,relative cholinergic hypoactivity was being implicated. Donepezil is a centrally acting reversible acetylcholinesterase inhibitor. It is approved for the treatment of Alzheimer's disease. In an open case series with standardized ratings, addition of donepezil 5-10 mg/day to ongoing mood-stabilizer treatment was associated with marked improvement in treatment-resistant mania. We want to conduct a 4-week randomized, double-blind, placebo-controlled trial of donepezil as augmentation of lithium in patients with acute manic episode to evaluate the safety and efficacy of donepezil as adjunctive treatment to mood stabilizers in bipolar disorder with acute mania.
As with other sulfonylurea-class hypoglycemics, many stable non-insulin-dependent diabetic patients receiving insulin may be safely placed on glipizide. When transferring patients from insulin to glipizide, the following general guidelines should be considered:

  * For patients whose daily insulin requirement is 20 units or less, insulin may be discontinued and glipizide therapy may begin at usual dosages. Several days should elapse between glipizide titration steps. 
  * For patients whose daily insulin requirement is greater than 20 units, the insulin dose should be reduced by 50% and glipizide therapy may begin at usual dosages. Subsequent reductions in insulin dosage should depend on individual patient response. Several days should elapse between glipizide titration steps. 



During the insulin withdrawal period, the patient should test urine samples for sugar and ketone bodies at least three times daily. Patients should be instructed to contact the prescriber immediately if these tests are abnormal. In some cases, especially when patient has been receiving greater than 40 units of insulin daily, it may be advisable to consider hospitalization during the transition period.
A prospective randomised control trial design was used. The study was carried out in a dental practice in Sudan, an under-developed country with lower social economic group. Children between 5-8 years were invited and selected if they met the inclusion criteria. Only those who had 1-2 carious primary molars needing PMCs were randomised. The PMCs were placed by a dentist in the CT arm and by a therapist in the HT arm. The children were follow up every 6 months up to 2 years. The demographic details, periodontal health, occlusion, children anxieties, and procedure time were recorded. The Kaplan-Meier survival rates for each arm were calculated. The incremental cost effectiveness ratio (ICER) was calculated using the results and the local salaries
Lumbar spine disorders often cause lower back pain, lower limb radiating pain, restricted movement, and neurological dysfunction, which seriously affect the quality of life of middle-aged and older people. It has been found that pathological changes in the spine often cause changes in the morphology and function of the paraspinal muscles (PSMs). Fatty infiltration (FI) in PSMs is closely associated with disc degeneration and Modic changes. And FI causes inflammatory responses that exacerbate the progression of lumbar spine disease and disrupt postoperative recovery. Magnetic resonance imaging can better distinguish between fat and muscle tissue with the threshold technique. Three-dimensional magnetic resonance imaging multi-echo imaging techniques such as water-fat separation and proton density are currently popular for studying FI. Muscle fat content obtained based on these imaging sequences has greater accuracy, visualization, acquisition speed, and utility. The proton density fat fraction calculated from these techniques has been shown to evaluate more subtle changes in PSMs. Magnetic resonance spectroscopy can accurately reflect the relationship between FI and the degeneration of PSMs by measuring intracellular and extracellular lipid values to quantify muscle fat. We have pooled and analyzed published studies and found that patients with spinal disorders often exhibit FI in PSMs. Some studies suggest an association between FI and adverse surgical outcomes, although conflicting results exist. These suggest that clinicians should consider FI when assessing surgical risks and outcomes. Future studies should focus on understanding the biological mechanisms underlying FI and its predictive value in spinal surgery, providing valuable insights for clinical decision-making.
The invention provides a traditional Chinese medicine foot skin-moistening paste. The Chinese medicine foot skin-moistening paste is composed of 25 parts of ginger juice, 25 parts of scallion juice, 100 parts of vinegar, 100 parts of oxhide gelatin, 30 parts of mirabilite, 25 parts of silver powder, 30 parts of yellow lead powder, 25 parts of artemisia powder, 25 parts of sesame oil, 25 parts of borneol, 30 parts of pterospermum heterophyllum, 30 parts of philippine flemingia root, 25 parts of fructus schizandrae, 50 parts of pine needles, 30 parts of radix rubiae, 100 parts of white wine and 30 parts of herba epimedii. The traditional Chinese medicine foot skin-moistening paste is prepared by the steps of immersing the ginger juice, the scallion juice, the pine needles, pterospermum heterophyllum, philippine flemingia root, fructus schizandrae, herba epimedii and radix rubiae in vinegar and white wine for 7 days; filtering and discarding residues; collecting filter solution; adding oxhide gelatin, mirabilite, the silver powder, the artemisia powder, sesame oil, borneol and the yellow lead powder into the filter solution; stirring uniformly; heating to a temperature of 90 DEG C; keeping the temperature for 45 minutes; stewing into a paste; and loading in bags or filling in bottles. When being in use, the foot skin-moistening paste is directly applied on the foot after pedicure, foot message and foot soaking. The foot skin-moistening paste has no adverse effect. The foot skin-moistening paste is simple in preparation, is safe and convenient for use, has good curative effect, is fast in action, has good clinic effect, and is convenient for popularization and application.
The method involves selecting a wrinkle (3) of a skin (1) of a human being, and selecting a pigment color e.g. permanent make-up color. The pigment color is applied in a skin area (11) or epidermis (5) that comprises a wrinkle. An application unit i.e. hollow needle, is arranged for applying partial coloring in the wrinkle. A mark is formed in a folding trench by a marking unit. The mark is provided along a lowering unit of the folding trench or along the wrinkle of the skin of the human being. Independent claims are also included for the following: (1) an application unit (2) a device for performing cosmetic treatment.
Vascular endothelial growth factor (VEGF) is a potent inducer of endothelial cell (EC) proliferation and migration in vitro, as well as inflammation in vivo. We showed recently that VEGF effect on vascular permeability was dependent on the synthesis of platelet-activating factor (PAF) by EC. Consequently, we sought to evaluate by antisense knockdown of gene expression the contribution of VEGF receptors (Flt-1 and Flk-1) on these events. VEGF (10-11 - 10-8M) elicited a dose-dependent increase of bovine aortic EC proliferation, migration and PAF synthesis by up to 2.05-, 1.31- and 35.9-fold above basal levels respectively. A treatment with two modified antisense oligomers (10-7- 5x10-7M) directed against Ftk-1 mRNA blocked by 100%, 91% and 85% the migration, proliferation and PAF synthesis mediated by VEGF  respectively. A treatment with two antisense oligomers directed against Flt-1 mRNA failed to modulate these activities. The use of placenta growth factor (10-8M), a Flt-1-specific agonist, induced only a slight increase (0.6-fold) of PAF synthesis. These data illustrate the crucial role of Flk-1 upon EC stimulation by VEGF. The capacity to inhibit the protein synthesis of Flt-1 and Flk-1 by antisense oligonucleotides provides a new approach to block VEGF pathological effects in vivo. Antagonists of VEGF  receptors, particularly the Flk-1 receptor, are contemplated as tools equivalent to the antisense molecules for their anti-angiogenic effect.
Children will not participate in the program until after their second assessment (between week 11 to 21). Their control period will take place between week 0 and 10.
NEW MATERIAL:A compound (salt) expressed by formula I (n is 1-25; X is O, S, N or CO; R is H, aliphatic acyl, alkoxycarbonyl, alkyl, heterocyclyl, phosphono, alkylphosphono, etc.). EXAMPLE:Rhizoxin 12-(propionyloxy)dodecanoic acid ester. USE:An antitumor agent. PREPARATION:For example, rhizoxin expressed by the formula RhzOH (Rhz is a group expressed by formula II) is dissolved in methylene chloride, etc., and 12-hydroxydodecanoic acid having protected hydroxyl group, etc., is then added to react and esterify the rhizoxin in the presence of carbodimides, etc. The protecting group of the hydroxyl group is then removed to provide rhizoxin 12-hydroxydodecanoic acid ester, which is subsequently dissolved in toluene, etc. Propionyl chloride, etc., are then dripped thereinto while cooling with ice and reacted therewith to afford the compound expressed by formula I.
Contraception

Based on animal studies with oral sirolimus, HYFTOR may cause fetal harm when administered to pregnant women. Females of reproductive potential are recommended to avoid becoming pregnant and to use an effective contraceptive method. Effective contraception should be initiated before HYFTOR therapy and used throughout treatment and for 12 weeks after the final dose of HYFTOR [see Warnings and Precautions (5.7), Use in Specific Populations (8.1)] . 

Infertility

Based on clinical findings and findings in animal studies, male and female fertility may be compromised by the treatment with sirolimus [see Warnings and Precautions (5.8), Nonclinical Toxicology (13.1)].  Ovarian cysts and menstrual disorders (including amenorrhea and menorrhagia) have been reported in females with the use of oral sirolimus. Azoospermia has been reported in males with the use of oral sirolimus and have been reversible upon discontinuation of sirolimus in most cases.
Gallbladder cancer (GBC) is the most common malignant tumor of the biliary system with the worst prognosis. Even after radical surgery, the majority of patients with GBC have difficulty achieving a clinical cure. The risk of tumor recurrence remains more than 65%, and the overall 5-year survival rate is less than 5%. The gut microbiota refers to a variety of microorganisms living in the human intestine, including bacteria, viruses and fungi, which profoundly affect the host state of general health, disease and even cancer. Over the past few decades, substantial evidence has supported that gut microbiota plays a critical role in promoting the progression of GBC. In this review, we summarize the functions, molecular mechanisms and recent advances of the intestinal microbiota in GBC. We focus on the driving role of bacteria in pivotal pathways, such as virulence factors, metabolites derived from intestinal bacteria, chronic inflammatory responses and ecological niche remodeling. Additionally, we emphasize the high level of correlation between viruses and fungi, especially EBV and Candida spp., with GBC. In general, this review not only provides a solid theoretical basis for the close relationship between gut microbiota and GBC but also highlights more potential research directions for further research in the future.
Patients in this arm will receive the Mobile Cardiac Telemetry device for 48-hour Holter monitoring as part of usual care. This device combines holter, event monitoring and mobile cardiac telemetry (continuous cardiac monitoring of every single beat) into one unit. The holter functionality will be used for the first 48 hours (usual care). The diagnostic yield from the 48 hour holter monitoring will be compared to the 15-day live monitoring.
Non-invasive ventilation (NIV) is a treatment that uses positive pressure delivered via a face mask or mouthpiece to assist a person to breathe. It can be used as a long-term treatment for people whose breathing is failing - usually due to chronic conditions that produce weakness of the respiratory muscles such as motor neurone disease / amyotrophic lateral sclerosis \[MND/ALS\]chronic obstructive pulmonary disease). Most people with MND/ALS use NIV at night initially. Even though NIV may improve survival and function, many are unable to use it for more than 4 hours per day (which is considered a threshold amount of use in order to gain a benefit) and many others are unable to tolerate it at all. Our team has recently provided evidence that specific and individualised titration of NIV leads to better outcomes in people with MND. This previous trial determined that the use of a sleep study (also called 'polysomnography') can improve the way people are initially set up with NIV. This study will replicate and extend the single site study in a large, multi-centre randomised controlled trial (RCT) across multiple sites This multi-centre RCT will also include a 12-month follow-up period to evaluate longer-term outcomes.